The relationship between pharmaceutical companies, the government, and the healthcare system raises significant legal and ethical questions. This article explores whether actions by these entities to block or limit access to affordable generic medications could be considered criminal negligence, manslaughter, or even murder. By examining legal frameworks and theoretical applications, the discussion delves into how these practices may infringe on public health, highlighting the ethical implications and the need for regulatory and corporate accountability.